Jay Bregman

Jay Bregman, CEO and co-founder of Andel, discusses how FDA’s action signals a broader regulatory recalibration aimed at protecting intellectual property and explores the second-order effects.

Jay Bregman, CEO and co-founder of Andel, discusses how pharmaceutical companies and digital health platforms may need to rethink commercialization strategies, shifting away from costly mass-market advertising toward employer-focused distribution models.

Jay Bregman, CEO and co-founder of Andel discusses how FDA’s planned action against non-FDA-approved GLP-1 products could reshape competition in obesity and diabetes care.

Jay Bregman, co-founder of Andel, closes out our conversation by explaining the impact government programs will have on GLP-1 coverage.

In the second part of our conversation, Andel co-founder Jay Bregman how new GLP-1 options hitting the market will amplify existing coverage problems for the near future.

Jay Bregman, co-founder of Andel, the cost and operational complexity of covering GLP-1 medications.